Universidad Peruana Cayetano Heredia

High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort

Mostrar el registro sencillo del ítem

dc.contributor.author Lalwani, P.
dc.contributor.author Araujo-Castillo, R.V.
dc.contributor.author Ganoza Gallardo, Christian Alejandro
dc.contributor.author Salgado, B.B.
dc.contributor.author Pereira Filho, I.V.
dc.contributor.author da Silva, D.S.S.
dc.contributor.author de Morais, T.B.D.N.
dc.contributor.author Jordão, M.F.
dc.contributor.author Ortiz, J.V.
dc.contributor.author Barbosa, A.R.C.
dc.contributor.author Sobrinho, W.B.S.
dc.contributor.author Cordeiro, I.B.
dc.contributor.author de Souza Neto, J.N.
dc.contributor.author de Assunção, E.N.
dc.contributor.author da Costa, C.F.
dc.contributor.author de Souza, P.E.
dc.contributor.author de Albuquerque, B.C.
dc.contributor.author Astofi-Filho, S.
dc.contributor.author Holanda, A.I.P.
dc.contributor.author Gomes, A.L.S.
dc.contributor.author França, A.P.S.D.
dc.contributor.author Monteiro, A.V.R.
dc.contributor.author Santos, A.D.P.
dc.contributor.author Teixeira, A.D.S.
dc.contributor.author Souza, A.V.S.D.
dc.contributor.author Pinheiro, B.
dc.contributor.author Santos, B.P.D.
dc.contributor.author Farias, B.P.
dc.contributor.author Paulino, B.N.
dc.contributor.author Silva, C.L.A.D.
dc.contributor.author Oliveira, C.I.F.B.D.
dc.contributor.author Martins, D.D.A.
dc.contributor.author Oliveira, E.A.D.
dc.contributor.author Carvalho, E.D.D.C.
dc.contributor.author Costa, E.F.D.
dc.contributor.author Simplicio, F.G.
dc.contributor.author Pereira, F.S.
dc.contributor.author Sinimbu, G.P.
dc.contributor.author Cardenes, G.D.O.
dc.contributor.author Silva, G.A.D.
dc.contributor.author Costa, I.S.F.D.
dc.contributor.author Correia, I.S.
dc.contributor.author Santos, I.G.C.D.
dc.contributor.author Guimarães, J.V.
dc.contributor.author Pinheiro, J.S.B.
dc.contributor.author Romana, J.C.
dc.contributor.author França, J.D.O.N.
dc.contributor.author Pinto, K.R.
dc.contributor.author Freitas, M.F.F.
dc.contributor.author Vasconcellos, M.C.D.
dc.contributor.author Moraes, M.C.
dc.contributor.author Damasceno, M.D.S.
dc.contributor.author Ruiz, M.A.
dc.contributor.author Lemos, M.M.C.D.
dc.contributor.author Picanço, N.S.
dc.contributor.author Maia, R.G.
dc.contributor.author Bezerra, R.C.
dc.contributor.author Souza, R.S.D.
dc.contributor.author Harjani, S.C.
dc.contributor.author Souza, V.B.D.
dc.contributor.author Melo, W.B.D.
dc.contributor.author Lalwani, J.D.B.
dc.contributor.author the DETECTCoV-19 Study Team
dc.date.accessioned 2021-12-12T20:24:58Z
dc.date.available 2021-12-12T20:24:58Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/10283
dc.description.abstract Background: The city of Manaus, Brazil, has seen two collapses of the health system due to the COVID-19 pandemic. We report anti-SARS-CoV-2 nucleocapsid IgG antibody seroconversion rates and associated risk factors in Manaus residents before the second wave of the epidemic in Brazil. Methods: A convenience sample of adult (aged ≥18 years) residents of Manaus was recruited through online and university website advertising into the DETECTCoV-19 study cohort. The current analysis of seroconversion included a subgroup of DETECTCoV-19 participants who had at least two serum sample collections separated by at least 4 weeks between Aug 19 and Oct 2, 2020 (visit 1), and Oct 19 and Nov 27, 2020 (visit 2). Those who reported (or had no data on) having a COVID-19 diagnosis before visit 1, and who were positive for anti-SARS-CoV-2 nucleocapsid IgG antibodies at visit 1 were excluded. Using an in-house ELISA, the reactivity index (RI; calculated as the optical density ratio of the sample to the negative control) for serum anti-SARS-CoV-2 nucleocapsid IgG antibodies was measured at both visits. We calculated the incidence of seroconversion (defined as RI values ≤1·5 at visit 1 and ≥1·5 at visit 2, and a ratio >2 between the visit 2 and visit 1 RI values) during the study period, as well as incidence rate ratios (IRRs) through cluster-corrected and adjusted Poisson regression models to analyse associations between seroconversion and variables related to sociodemographic characteristics, health access, comorbidities, COVID-19 exposure, protective behaviours, and symptoms. Findings: 2496 DETECTCoV-19 cohort participants returned for a follow-up visit between Oct 19 and Nov 27, 2020, of whom 204 reported having COVID-19 before the first visit and 24 had no data regarding previous disease status. 559 participants were seropositive for anti-SARS-CoV-2 nucleocapsid IgG antibodies at baseline. Of the remaining 1709 participants who were seronegative at baseline, 71 did not meet the criteria for seroconversion and were excluded from the analyses. Among the remaining 1638 participants who were seronegative at baseline, 214 showed seroconversion at visit 2. The seroconversion incidence was 13·06% (95% CI 11·52–14·79) overall and 6·78% (5·61–8·10) for symptomatic seroconversion, over a median follow-up period of 57 days (IQR 54–61). 48·1% of seroconversion events were estimated to be asymptomatic. The sample had higher proportions of affluent and higher-educated people than those reported for the Manaus city population. In the fully adjusted and corrected model, risk factors for seroconversion before visit 2 were having a COVID-19 case in the household (IRR 1·49 [95% CI 1·21–1·83]), not wearing a mask during contact with a person with COVID-19 (1·25 [1·09–1·45]), relaxation of physical distancing (1·31 [1·05–1·64]), and having flu-like symptoms (1·79 [1·23–2·59]) or a COVID-19 diagnosis (3·57 [2·27–5·63]) between the first and second visits, whereas working remotely was associated with lower incidence (0·74 [0·56–0·97]). Interpretation: An intense infection transmission period preceded the second wave of COVID-19 in Manaus. Several modifiable behaviours increased the risk of seroconversion, including non-compliance with non-pharmaceutical interventions measures such as not wearing a mask during contact, relaxation of protective measures, and non-remote working. Increased testing in high-transmission areas is needed to provide timely information about ongoing transmission and aid appropriate implementation of transmission mitigation measures en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Lancet. Global health
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject adult en_US
dc.subject Article en_US
dc.subject Brazil en_US
dc.subject cohort analysis en_US
dc.subject controlled study en_US
dc.subject coronavirus disease 2019 en_US
dc.subject diagnostic test accuracy study en_US
dc.subject disease transmission en_US
dc.subject education en_US
dc.subject enzyme linked immunosorbent assay en_US
dc.subject Escherichia coli en_US
dc.subject female en_US
dc.subject government en_US
dc.subject human en_US
dc.subject immunoglobulin G antibody en_US
dc.subject incidence en_US
dc.subject income en_US
dc.subject major clinical study en_US
dc.subject male en_US
dc.subject nucleocapsid protein en_US
dc.subject oropharyngeal swab en_US
dc.subject prospective study en_US
dc.subject questionnaire en_US
dc.subject receiver operating characteristic en_US
dc.subject risk factor en_US
dc.subject SARS-CoV-2 antibody en_US
dc.subject sensitivity analysis en_US
dc.subject sensitivity and specificity en_US
dc.subject seroconversion en_US
dc.subject size exclusion chromatography en_US
dc.subject social behavior en_US
dc.subject social distancing en_US
dc.subject socioeconomics en_US
dc.subject virus nucleocapsid en_US
dc.title High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/S2214-109X(21)00355-7
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.05
dc.relation.issn 2214-109X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas